New immunotherapy option for High-Risk pancreatic cancer patients
NCT ID NCT07083479
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target and destroy any remaining cancer cells. It is for patients who have no other treatment options and cannot join a clinical trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- A sound wave that could expose hidden pancreatic cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?